Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a randomised, double‐blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.
Epistemonikos ID: 71dc921b86d673c13c90a3e589886612dc6babf2
First added on: May 21, 2024